Developer docs
API playgroundTry for free, no card

Search company profiles

Nanoscope Therapeutics

Full company profile

uuid000089m

Namestring
Nanoscope Therapeutics
Legal namestring
Nanoscope Therapeutics, Inc.
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Nanoscope Therapeutics, Inc. is a privately held, late-stage clinical biotechnology company headquartered in Dallas, Texas, developing disease-agnostic, mutation-agnostic optogenetic gene therapies for retinal degenerative diseases. The company's core technology is the proprietary Multi-Characteristic Opsin (MCO) platform, which delivers light-sensitive opsins to bipolar retinal cells so they become photosensitive, bypassing degenerated photoreceptors without requiring genetic testing, invasive surgery, or repeat dosing. Its lead asset, MCO-010 (brand name MOGENRY; INN: sonpiretigene isteparvovec), is an AAV-delivered, one-time intravitreal therapy advancing through a rolling Biologics License Application to the FDA for retinitis pigmentosa (RP), with a Phase 2 trial completed in Stargardt disease (STARLIGHT) and a Phase 3 planned. A non-viral, laser-delivered second asset, MCO-020, targets geographic atrophy (GA) with a Phase 2 program expected in 2026, and an IND-ready Leber congenital amaurosis (LCA) program extends the pipeline.

Nanoscope's business model is one-time gene therapy administration — a single intravitreal injection administered by retinal specialists in-office, reimbursed at premium gene-therapy pricing once approved. The company has secured US distribution through InspiroGene by McKesson for specialty pharmacy, distribution, and patient hub services post-approval. Revenue is not yet recognized (pre-commercial); the company funds operations through venture capital, a disclosed $1.5M NIH SBIR grant (2021), and the implicit assumption of subsequent un-disclosed financing rounds. Currently 11-50 employees, it is rapidly scaling a commercial leadership bench (COO Paul Hallen from Alcon; CFO Michael Marquez; SVP Sales & Marketing Ashish Patel; SVP Regulatory & Quality Khandan Baradaran).

The company's competitive position rests on a broad patent estate (US Patent No. 12459977 through 2039, plus corresponding patents in Australia and Japan and pending applications in China and EU; co-founder/CSO Samarendra Mohanty holds 200+ international patents), a multi-jurisdiction regulatory footprint (FDA Fast Track, Orphan Drug, and RMAT designations; Japan MHLW Sakigake and Orphan Drug — a first for a retinal gene therapy; five EMA Orphan designations; Saudi Arabia Orphan), and durable clinical data (REMAIN 152-week follow-up showing ~0.3 LogMAR sustained visual acuity gain with no serious adverse events). Markets served include RP (~100,000 US patients, 25,000+ legally blind), Stargardt disease (~41,000 US patients, 1M+ worldwide), GA, and LCA, with regulatory pre-commercialization work underway across US, Japan, EU, and Saudi Arabia.

Short descriptiontext

Nanoscope Therapeutics is a Dallas-based, pre-commercial clinical-stage biotech developing disease-agnostic optogenetic gene therapies (Multi-Characteristic Opsin platform) to restore vision in patients with retinal degenerative diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDallas, United States
HQ citystring
Dallas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
optogenetic gene therapy, retinal degenerative diseases, vision restoration therapy, ophthalmic biologics, mutation-agnostic therapy
Industry4 codes
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
Ophthalmic Gene Therapy
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pre-revenue / Pre-commercialization stage
TypeOne Time License
Description

Nanoscope Therapeutics is pre-commercial with no product revenue; lead asset MCO-010 (brand name MOGENRY) is advancing through regulatory submission with rolling BLA initiated with FDA. Future revenue model will be one-time gene therapy administration (intravitreal injection) for retinal degenerative diseases, sold through specialty pharmacy and distribution channels (InspiroGene by McKesson).

nanostherapeutics.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Pricing details1 tier
1Pricing not publicly disclosed
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. Future pricing expected to be one-time premium pricing for gene therapy, with potential support from Japan's Sakigake designation.

prnewswire.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1MOGENRY
Description

Trade name for MCO-010, the company's lead optogenetic gene therapy asset being advanced for retinitis pigmentosa toward FDA approval.

prnewswire.com
+2 more records
Core offering1 text field

Nanoscope Therapeutics develops disease-agnostic, mutation-agnostic optogenetic gene therapies using its proprietary Multi-Characteristic Opsin (MCO) platform to restore vision in patients with retinal degenerative diseases such as Retinitis Pigmentosa (RP), Stargardt Disease (SD), Geographic Atrophy (GA), and Leber Congenital Amaurosis (LCA). The lead asset MCO-010 (MOGENRY; INN: sonpiretigene isteparvovec) is a one-time, in-office intravitreal AAV-delivered gene therapy with a rolling BLA submission underway for RP, while MCO-020 is a non-viral laser-delivered optogenetic therapy in preclinical development for GA.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • ~0.3 LogMAR visual acuity gain sustained over 152 weeks (3 years) in REMAIN study with no serious adverse events
+3 more records
Product overview1 text field

Nanoscope Therapeutics offers a unified optogenetic therapy platform centered on its proprietary Multi-Characteristic Opsin (MCO) technology for vision restoration in patients with retinal degenerative diseases. The platform architecture consists of the core MCO Platform (broadband, fast response, ultra-sensitive optogenetic technology) supporting distinct therapeutic products including the lead MCO-010 (MOGENRY) AAV-delivered therapy for retinitis pigmentosa and Stargardt disease, and the non-viral MCO-020 therapy in development for geographic atrophy. Additional IND-ready programs include Leber congenital amaurosis (LCA). The MCO Platform enables disease-agnostic treatment through a single intravitreal injection approach that activates bipolar retinal cells to become light-sensitive without requiring genetic testing, supported by the MLSDT functional vision assessment tool used in clinical trials.

Product and service2 records
1MCO-010 (MOGENRY)
CategoryLead therapeutic product
Description

One-time, in-office, intravitreal disease-agnostic AAV-delivered optogenetic gene therapy that activates bipolar retinal cells to become light-sensitive, restoring vision in patients with photoreceptor degeneration. Lead asset in rolling BLA for Retinitis Pigmentosa and in Phase 2 STARLIGHT trial for Stargardt Disease.

2MCO-020
CategoryPipeline therapeutic product
Description

Non-viral optogenetic therapy using laser-delivered gene therapy for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Currently in preclinical development with biodistribution data demonstrated in primates.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
1Women In Bio (WIB)
Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2026-06-22
Description

CEO Sulagna Bhattacharya participating as a speaker in a Women In Bio (WIB) executive leadership panel discussion at the 2026 BIO International Convention titled 'Building Resilient Organizations in an Era of Uncertainty' alongside CEOs and senior leaders across science, capital, and organizational transformation.

nanostherapeutics.com
Strategic tierFlagshipTypeChannel Partner/ Reseller/ DistributorAnnounced on2026-05-27
Description

Selected InspiroGene by McKesson to provide U.S. commercialization services for Nanoscope's lead product MOGENRY (MCO-010), subject to FDA approval. InspiroGene will support U.S. distribution through specialty pharmacy, specialty distribution, and patient hub services focused on US commercialization and supply chain. The collaboration positions Nanoscope to launch the first optogenetic gene therapy for the U.S. market, providing best-in-class experience for patients and providers. Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, is the named counterpart; engagement initiated under COO Paul Hallen and CEO Sulagna Bhattacharya.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-25
Description

Verana Health and Nanoscope Therapeutics announced a collaboration to accelerate retinitis pigmentosa research. Verana Health provides real-world data and clinical research insights leveraging its specialty data networks and AI capabilities, while Nanoscope brings its MCO optogenetic therapy pipeline for RP. The collaboration is positioned to advance understanding of RP patient populations and support clinical development and commercialization planning.

4Max Planck Society (Max Planck Institute)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-30
Description

Nanoscope Therapeutics licensed optogenetic catch technology from the Max Planck Society. The licensing arrangement covers proprietary optogenetic catch technology originating from the Max Planck Institute, providing Nanoscope with foundational IP rights for its MCO platform and extending its technology base. Disclosed September 30, 2024.

nanostherapeutics.com
5Max Planck Society (Optogenetic Catch Technology)
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-09-30
Description

Already captured above under Max Planck Society — included once per partner to avoid duplication.

nanostherapeutics.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Closest direct competitor: French clinical-stage biotech developing optogenetic gene therapy (GS030, AAV2-based ChRtdimR opsin via AAV2 intravitreal injection with wearable goggles) for retinitis pigmentosa. Same optogenetic therapeutic approach targeting retinal ganglion cells via AAV delivery, and most advanced competing optogenetic program globally.

TypeDirect peer
Description

Clinical-stage gene therapy company developing ixoberogene soroparvovec (Ixo-vec) for wet AMD and diabetic macular edema. Similar ophthalmology gene therapy pipeline structure, AAV-based delivery, retina specialist customer base, and U.S. clinical-stage status.

TypeDirect peer
Description

Clinical-stage gene therapy company with ophthalmology programs including botaretigene sparoparvovec (AAV-RPGR) for X-linked retinitis pigmentosa, developed with Janssen. Direct overlap in RP gene therapy development and AAV intravitreal delivery.

TypeDirect peer
Description

Clinical/commercial-stage AAV gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy, developed with AbbVie. Overlapping AAV delivery platform, retina specialist customer base, and gene therapy pipeline structure.

TypeDirect peer
Description

Acquired by Roche; developed and commercializes voretigene neparvovec (Luxturna), the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65). Reference benchmark for retinal gene therapy pricing, distribution, and regulatory pathway that Nanoscope must navigate.

TypeEmerging player
Description

Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including Leber congenital amaurosis (LCA1) and X-linked retinitis pigmentosa (XLRP). Overlapping RP/LCA patient population and AAV delivery modality, with Phase 1/2 readouts expected.

TypeEmerging player
Description

Clinical-stage CRISPR-based gene editing company developing EDIT-101 for LCA10 (Leber congenital amaurosis type 10) and EDIT-301 for sickle cell disease. Partial overlap in LCA indication with Nanoscope's LCA program and shared ophthalmology gene therapy focus.

TypeEmerging player
Description

French clinical-stage gene therapy company developing AAV-based therapies for retinal degenerative diseases including RP and Stargardt disease. Direct disease-area overlap and emerging pipeline positioning relative to Nanoscope's MCO-010.

TypeEmerging player
Description

Clinical-stage AAV gene therapy company developing therapies for inherited retinal diseases including X-linked retinitis pigmentosa. Earlier-stage peer with similar retinal gene therapy pipeline structure and AAV-based delivery.

TypeBroad incumbent
Description

Largest dedicated ophthalmology medical device and pharmaceutical company, employer of Nanoscope's COO Paul Hallen and CFO Michael Marquez. Alcon provides broad retinal surgery, IOL, and pharmaceutical products and represents both a competitor in retinal care and the dominant acquirer/employer of senior retinal commercial talent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Nanoscope Therapeutics

Ophthalmic Gene Therapynanostherapeutics.com

Nanoscope Therapeutics is a Dallas-based, pre-commercial clinical-stage biotech developing disease-agnostic optogenetic gene therapies (Multi-Characteristic Opsin platform) to restore vision in patients with retinal degenerative diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

What Nanoscope Therapeutics does

Nanoscope Therapeutics, Inc. is a privately held, late-stage clinical biotechnology company headquartered in Dallas, Texas, developing disease-agnostic, mutation-agnostic optogenetic gene therapies for retinal degenerative diseases. The company's core technology is the proprietary Multi-Characteristic Opsin (MCO) platform, which delivers light-sensitive opsins to bipolar retinal cells so they become photosensitive, bypassing degenerated photoreceptors without requiring genetic testing, invasive surgery, or repeat dosing. Its lead asset, MCO-010 (brand name MOGENRY; INN: sonpiretigene isteparvovec), is an AAV-delivered, one-time intravitreal therapy advancing through a rolling Biologics License Application to the FDA for retinitis pigmentosa (RP), with a Phase 2 trial completed in Stargardt disease (STARLIGHT) and a Phase 3 planned. A non-viral, laser-delivered second asset, MCO-020, targets geographic atrophy (GA) with a Phase 2 program expected in 2026, and an IND-ready Leber congenital amaurosis (LCA) program extends the pipeline.

Nanoscope's business model is one-time gene therapy administration — a single intravitreal injection administered by retinal specialists in-office, reimbursed at premium gene-therapy pricing once approved. The company has secured US distribution through InspiroGene by McKesson for specialty pharmacy, distribution, and patient hub services post-approval. Revenue is not yet recognized (pre-commercial); the company funds operations through venture capital, a disclosed $1.5M NIH SBIR grant (2021), and the implicit assumption of subsequent un-disclosed financing rounds. Currently 11-50 employees, it is rapidly scaling a commercial leadership bench (COO Paul Hallen from Alcon; CFO Michael Marquez; SVP Sales & Marketing Ashish Patel; SVP Regulatory & Quality Khandan Baradaran).

The company's competitive position rests on a broad patent estate (US Patent No. 12459977 through 2039, plus corresponding patents in Australia and Japan and pending applications in China and EU; co-founder/CSO Samarendra Mohanty holds 200+ international patents), a multi-jurisdiction regulatory footprint (FDA Fast Track, Orphan Drug, and RMAT designations; Japan MHLW Sakigake and Orphan Drug — a first for a retinal gene therapy; five EMA Orphan designations; Saudi Arabia Orphan), and durable clinical data (REMAIN 152-week follow-up showing ~0.3 LogMAR sustained visual acuity gain with no serious adverse events). Markets served include RP (~100,000 US patients, 25,000+ legally blind), Stargardt disease (~41,000 US patients, 1M+ worldwide), GA, and LCA, with regulatory pre-commercialization work underway across US, Japan, EU, and Saudi Arabia.

Nanoscope Therapeutics firmographics

Firmographics
Name
Nanoscope Therapeutics
Legal name
Nanoscope Therapeutics, Inc.
Website
https://nanostherapeutics.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Nanoscope Therapeutics is a Dallas-based, pre-commercial clinical-stage biotech developing disease-agnostic optogenetic gene therapies (Multi-Characteristic Opsin platform) to restore vision in patients with retinal degenerative diseases including retinitis pigmentosa, Stargardt disease, and geographic atrophy.
Ownership category
akta.pro rank

Nanoscope Therapeutics industry classification

Industry
Product category
Ophthalmic Gene Therapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAACAG
Ophthalmology Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAACAE
Gene Therapy for Rare/Monogenic Diseases
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAIAIAK
Rare Ophthalmology Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAAACAH
Neurology/CNS Gene Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)

Keywords

  • Optogenetic gene therapy
  • Retinal degenerative diseases
  • Vision restoration therapy
  • Ophthalmic biologics
  • Mutation-agnostic therapy

Where Nanoscope Therapeutics is headquartered

Location

Headquarters

HQ city
Dallas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Nanoscope Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Pre-revenue / Pre-commercialization stage: Nanoscope Therapeutics is pre-commercial with no product revenue; lead asset MCO-010 (brand name MOGENRY) is advancing through regulatory submission with rolling BLA initiated with FDA. Future revenue model will be one-time gene therapy administration (intravitreal injection) for retinal degenerative diseases, sold through specialty pharmacy and distribution channels (InspiroGene by McKesson).

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractPricing not publicly disclosed

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Nanoscope Therapeutics product offering

Product offering

Core offering

Nanoscope Therapeutics develops disease-agnostic, mutation-agnostic optogenetic gene therapies using its proprietary Multi-Characteristic Opsin (MCO) platform to restore vision in patients with retinal degenerative diseases such as Retinitis Pigmentosa (RP), Stargardt Disease (SD), Geographic Atrophy (GA), and Leber Congenital Amaurosis (LCA). The lead asset MCO-010 (MOGENRY; INN: sonpiretigene isteparvovec) is a one-time, in-office intravitreal AAV-delivered gene therapy with a rolling BLA submission underway for RP, while MCO-020 is a non-viral laser-delivered optogenetic therapy in preclinical development for GA.

Product overview

Nanoscope Therapeutics offers a unified optogenetic therapy platform centered on its proprietary Multi-Characteristic Opsin (MCO) technology for vision restoration in patients with retinal degenerative diseases. The platform architecture consists of the core MCO Platform (broadband, fast response, ultra-sensitive optogenetic technology) supporting distinct therapeutic products including the lead MCO-010 (MOGENRY) AAV-delivered therapy for retinitis pigmentosa and Stargardt disease, and the non-viral MCO-020 therapy in development for geographic atrophy. Additional IND-ready programs include Leber congenital amaurosis (LCA). The MCO Platform enables disease-agnostic treatment through a single intravitreal injection approach that activates bipolar retinal cells to become light-sensitive without requiring genetic testing, supported by the MLSDT functional vision assessment tool used in clinical trials.

Differentiator

Problem solved

Functional benefit

Brands

  • MOGENRY: Trade name for MCO-010, the company's lead optogenetic gene therapy asset being advanced for retinitis pigmentosa toward FDA approval.
  • MCO Platform
  • MCO-010

Products and services

  • MCO-010 (MOGENRY) One-time, in-office, intravitreal disease-agnostic AAV-delivered optogenetic gene therapy that activates bipolar retinal cells to become light-sensitive, restoring vision in patients with photoreceptor degeneration. Lead asset in rolling BLA for Retinitis Pigmentosa and in Phase 2 STARLIGHT trial for Stargardt Disease.
  • MCO-020 Non-viral optogenetic therapy using laser-delivered gene therapy for geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Currently in preclinical development with biodistribution data demonstrated in primates.

Quantifiable outcome

  • ~0.3 LogMAR visual acuity gain sustained over 152 weeks (3 years) in REMAIN study with no serious adverse events
  • +3 more outcomes

Companies that use Nanoscope Therapeutics

Customer profile

Named customers3 records

Segments5 records

Ideal customer profiles2 records

Nanoscope Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Nanoscope Therapeutics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor, flagship and core.

  • Women In Bio (WIB)minorGTM or Marketing Partner · 22 June 2026CEO Sulagna Bhattacharya participating as a speaker in a Women In Bio (WIB) executive leadership panel discussion at the 2026 BIO International Convention titled 'Building Resilient Organizations in an Era of Uncertainty' alongside CEOs and senior leaders across science, capital, and organizational transformation.
  • InspiroGene by McKessonflagshipChannel Partner/ Reseller/ Distributor · 27 May 2026Selected InspiroGene by McKesson to provide U.S. commercialization services for Nanoscope's lead product MOGENRY (MCO-010), subject to FDA approval. InspiroGene will support U.S. distribution through specialty pharmacy, specialty distribution, and patient hub services focused on US commercialization and supply chain. The collaboration positions Nanoscope to launch the first optogenetic gene therapy for the U.S. market, providing best-in-class experience for patients and providers. Joe DePinto, Head of Cell, Gene, and Advanced Therapies at McKesson, is the named counterpart; engagement initiated under COO Paul Hallen and CEO Sulagna Bhattacharya.
  • Verana HealthcoreStrategic or Co-development Partner · 25 February 2025Verana Health and Nanoscope Therapeutics announced a collaboration to accelerate retinitis pigmentosa research. Verana Health provides real-world data and clinical research insights leveraging its specialty data networks and AI capabilities, while Nanoscope brings its MCO optogenetic therapy pipeline for RP. The collaboration is positioned to advance understanding of RP patient populations and support clinical development and commercialization planning.
  • Max Planck Society (Max Planck Institute)coreOEM/ Whitelabel/ Licensing Partner · 30 September 2024Nanoscope Therapeutics licensed optogenetic catch technology from the Max Planck Society. The licensing arrangement covers proprietary optogenetic catch technology originating from the Max Planck Institute, providing Nanoscope with foundational IP rights for its MCO platform and extending its technology base. Disclosed September 30, 2024.
  • Max Planck Society (Optogenetic Catch Technology)coreOEM/ Whitelabel/ Licensing Partner · 30 September 2024Already captured above under Max Planck Society — included once per partner to avoid duplication.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Nanoscope Therapeutics competitors and assessment

Company assessment

Direct peers

  • GenSight Biologics: Closest direct competitor: French clinical-stage biotech developing optogenetic gene therapy (GS030, AAV2-based ChRtdimR opsin via AAV2 intravitreal injection with wearable goggles) for retinitis pigmentosa. Same optogenetic therapeutic approach targeting retinal ganglion cells via AAV delivery, and most advanced competing optogenetic program globally.
  • Adverum Biotechnologies: Clinical-stage gene therapy company developing ixoberogene soroparvovec (Ixo-vec) for wet AMD and diabetic macular edema. Similar ophthalmology gene therapy pipeline structure, AAV-based delivery, retina specialist customer base, and U.S. clinical-stage status.
  • MeiraGTx: Clinical-stage gene therapy company with ophthalmology programs including botaretigene sparoparvovec (AAV-RPGR) for X-linked retinitis pigmentosa, developed with Janssen. Direct overlap in RP gene therapy development and AAV intravitreal delivery.
  • Regenxbio: Clinical/commercial-stage AAV gene therapy company with ABBV-RGX-314 for wet AMD and diabetic retinopathy, developed with AbbVie. Overlapping AAV delivery platform, retina specialist customer base, and gene therapy pipeline structure.
  • Spark Therapeutics: Acquired by Roche; developed and commercializes voretigene neparvovec (Luxturna), the first FDA-approved AAV gene therapy for an inherited retinal disease (RPE65). Reference benchmark for retinal gene therapy pricing, distribution, and regulatory pathway that Nanoscope must navigate.

Emerging players

  • Atsena Therapeutics: Clinical-stage gene therapy company developing AAV-based therapies for inherited retinal diseases including Leber congenital amaurosis (LCA1) and X-linked retinitis pigmentosa (XLRP). Overlapping RP/LCA patient population and AAV delivery modality, with Phase 1/2 readouts expected.
  • Editas Medicine: Clinical-stage CRISPR-based gene editing company developing EDIT-101 for LCA10 (Leber congenital amaurosis type 10) and EDIT-301 for sickle cell disease. Partial overlap in LCA indication with Nanoscope's LCA program and shared ophthalmology gene therapy focus.
  • Coave Therapeutics: French clinical-stage gene therapy company developing AAV-based therapies for retinal degenerative diseases including RP and Stargardt disease. Direct disease-area overlap and emerging pipeline positioning relative to Nanoscope's MCO-010.
  • Applied Genetic Technologies Corporation (AGTC): Clinical-stage AAV gene therapy company developing therapies for inherited retinal diseases including X-linked retinitis pigmentosa. Earlier-stage peer with similar retinal gene therapy pipeline structure and AAV-based delivery.

Broad incumbents

  • Alcon: Largest dedicated ophthalmology medical device and pharmaceutical company, employer of Nanoscope's COO Paul Hallen and CFO Michael Marquez. Alcon provides broad retinal surgery, IOL, and pharmaceutical products and represents both a competitor in retinal care and the dominant acquirer/employer of senior retinal commercial talent.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Nanoscope Therapeutics social profiles

Digital presence

Nanoscope Therapeutics compliance and trust

Trust signal

Compliance3 records

Nanoscope Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Nanoscope Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Nanoscope Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Nanoscope Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nanoscope Therapeutics

What does Nanoscope Therapeutics do?

Nanoscope Therapeutics develops disease-agnostic, mutation-agnostic optogenetic gene therapies using its proprietary Multi-Characteristic Opsin (MCO) platform to restore vision in patients with retinal degenerative diseases such as Retinitis Pigmentosa (RP), Stargardt Disease (SD), Geographic Atrophy (GA), and Leber Congenital Amaurosis (LCA). The lead asset MCO-010 (MOGENRY; INN: sonpiretigene isteparvovec) is a one-time, in-office intravitreal AAV-delivered gene therapy with a rolling BLA submission underway for RP, while MCO-020 is a non-viral laser-delivered optogenetic therapy in preclinical development for GA.

Is Nanoscope Therapeutics a public or private company?

Nanoscope Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Nanoscope Therapeutics founded?

Nanoscope Therapeutics was founded in 2021. It employs 11 to 50 people.

Where is Nanoscope Therapeutics based?

Nanoscope Therapeutics is headquartered in Dallas, United States, in the North America region.

How does Nanoscope Therapeutics make money?

One revenue line is on record: pre-revenue / Pre-commercialization stage.

Who are Nanoscope Therapeutics's main competitors?

Direct peers on record are GenSight Biologics, Adverum Biotechnologies, MeiraGTx, Regenxbio and Spark Therapeutics. Emerging players are Atsena Therapeutics, Editas Medicine, Coave Therapeutics and Applied Genetic Technologies Corporation (AGTC). Alcon is listed as a broad incumbent.

Does Nanoscope Therapeutics have an API?

No public API is recorded for Nanoscope Therapeutics.

What industry is Nanoscope Therapeutics in?

Nanoscope Therapeutics's product category is Ophthalmic Gene Therapy. Its primary akta.pro industry code is HLAAACAG, Ophthalmology Gene Therapies, with a secondary code of HLAAACAE, Gene Therapy for Rare/Monogenic Diseases. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogNanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY® Across the Gulf Cooperation Council RegionNanoscope Therapeutics and Uniphar agreed that Uniphar will be the exclusive named patient sales and commercialization partner for MOGENRY in the six GCC countries. The partnership enables named patient supply for eligible patients with inherited retinal dystrophies ahead of local regulatory approvals, with regional commercialization to follow.FinancialContent Business PageNanoscope Therapeutics Partners with Uniphar to Expand Access to MOGENRY® Across the Gulf Cooperation Council RegionNanoscope Therapeutics and Uniphar agreed that Uniphar will serve as the exclusive named patient sales and commercialization partner for MOGENRY in the six GCC countries. The partnership enables named patient supply for eligible patients with inherited retinal dystrophies ahead of local regulatory approvals, with regional commercialization to follow.The Times of IndiaHow one injection could restore sight for millions of IndiansScientists at Nanoscope Therapeutics developed MOGENRY, an optogenetic gene therapy for retinitis pigmentosa, an inherited retinal disorder. The disease affects about 1 in 1,000 people in India, with over a million cases. Optogenetics was recognized with the 2026 Nobel Prize in Physiology or Medicine.The Times of IndiaNew eye treatment a ray of hope for millions of IndiansNanoscope Therapeutics developed MOGENRY, an optogenetic gene therapy for retinitis pigmentosa, with a one-time injection restoring light response in surviving retinal cells. In a trial at Cuttack Eye Hospital, seven of eight patients showed measurable vision improvement. The therapy is under regulatory review, with the US FDA accepting its Biologics License Application.PR NewswireNanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory AffairsNanoscope Therapeutics appointed Damon Daulerio as Executive Director of Regulatory Affairs, bringing 30 years of pharmaceutical industry experience. The appointment supports MOGENRY's FDA and PMDA review of its Biologics License Application and Japan New Drug Application. The company continues building clinical and regulatory readiness for potential approval.PR NewswireNanoscope Therapeutics Appoints Ophthalmology and Rare Disease Regulatory Leader Damon Daulerio as Executive Director of Regulatory AffairsNanoscope Therapeutics appointed Damon Daulerio as Executive Director of Regulatory Affairs, bringing 30 years of pharmaceutical regulatory experience. The appointment supports MOGENRY's FDA and PMDA review of its BLA and JNDA for inherited retinal dystrophies. The company continues building clinical and regulatory readiness for potential approval.Dallas InnovatesNanoscope Therapeutics Hires Troy Short to Run Supply ChainNanoscope Therapeutics hired Troy Short as senior vice president of manufacturing and supply chain ahead of FDA approval for its gene therapy Mogenry. Short previously led supply chain for Zolgensma at AveXis. The company has received $12.8 million in funding and is preparing for the drug's launch.citybizNanoscope Therapeutics Appoints Troy Short SVP of Manufacturing and Supply Chain Ahead of Potential MOGENRY LaunchNanoscope Therapeutics appointed Troy Short as Senior Vice President of Manufacturing and Supply Chain ahead of potential MOGENRY launch. Short will oversee GMP operations and global distribution as the gene therapy undergoes regulatory review in the U.S. and Japan. The company plans a Phase 3 study for Stargardt disease in 2026.PR NewswireNanoscope Therapeutics Appoints Gene Therapy Operations Leader Troy Short as Senior Vice President, Manufacturing and Supply ChainNanoscope Therapeutics appointed Troy Short as Senior Vice President, Manufacturing and Supply Chain, to lead GMP manufacturing and global distribution for MOGENRY. The company's BLA for MOGENRY is under FDA review, with a Japan NDA also in progress. Short will focus on strengthening manufacturing partnerships and supply chain resilience for potential approval.